Literature DB >> 12086762

Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease.

Barbara C Biedermann1, Silvia Sahner, Michael Gregor, Dimitrios A Tsakiris, Christina Jeanneret, Jordan S Pober, Alois Gratwohl.   

Abstract

BACKGROUND: Vascular endothelial cells form the interface between recipient tissues and circulating alloreactive donor T cells after allogeneic stem cell transplantation. Vascular injury has been seen in patients with acute graft versus host disease (GVHD) in the skin. We aimed to see whether vascular injury mediated by cytotoxic T lymphocytes and microvessel loss arises in patients with chronic GVHD.
METHODS: We investigated eight patients with acute GVHD and ten with chronic GVHD for signs of endothelial injury and microvessel loss by measurement of von Willebrand factor (vWF) in plasma and blood vessel density in biopsy samples taken from lesional skin. Controls consisted of nine patients without GVHD who survived for longer than 100 days and nine healthy people. Inflammation and endothelial injury were assessed in selected samples by immunostaining for CD8 T cells, activated cytotoxic T lymphocytes, and vascular endothelial cells.
FINDINGS: We identified more extensive loss of microvessels in the skin of patients with GVHD (median 66 capillaries/mm(2); IQR 16-98) than of healthy controls (205 capillaries/mm(2); 157-226; p=0.005). Patients with GVHD had higher concentrations of vWF (238%; 168-288) than did those without GVHD (102%; 88-118; p=0.0005). Perivascular CD8 T cell infiltrates in skin correlated with vWF plasma concentrations in patients with GVHD (p=0.01), and activated cytotoxic T lymphocytes and endothelial injury were present in these same samples.
INTERPRETATION: Host endothelial cells are a target of alloreactive donor cytotoxic T lymphocytes. Substantial blood vessel loss may lead to impaired blood perfusion and tissue fibrosis, the hallmark lesion of chronic GVHD.

Entities:  

Mesh:

Year:  2002        PMID: 12086762     DOI: 10.1016/S0140-6736(02)08907-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  73 in total

1.  Numerical impairment of nestin(+) bone marrow niches in acute GvHD after allogeneic hematopoietic stem cell transplantation for AML.

Authors:  M Medinger; W Krenger; A Jakab; J Halter; A Buser; C Bucher; J Passweg; A Tzankov
Journal:  Bone Marrow Transplant       Date:  2015-08-24       Impact factor: 5.483

2.  Nuclear factor κB inhibition reduces lung vascular lumen obliteration in severe pulmonary hypertension in rats.

Authors:  Daniela Farkas; Aysar A Alhussaini; Donatas Kraskauskas; Vita Kraskauskiene; Carlyne D Cool; Mark R Nicolls; Ramesh Natarajan; Laszlo Farkas
Journal:  Am J Respir Cell Mol Biol       Date:  2014-09       Impact factor: 6.914

3.  Genetic variation in bactericidal/permeability-increasing protein influences the risk of developing rapid airflow decline after hematopoietic cell transplantation.

Authors:  Jason W Chien; Lue Ping Zhao; John A Hansen; Wen Hong Fan; Tanyalak Parimon; Joan G Clark
Journal:  Blood       Date:  2005-11-22       Impact factor: 22.113

4.  Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.

Authors:  J Labrador; L López-Corral; O López-Godino; L Vázquez; M Cabrero-Calvo; R Pérez-López; M Díez-Campelo; F Sánchez-Guijo; E Pérez-López; C Guerrero; I Alberca; M C Del Cañizo; J A Pérez-Simón; J R González-Porras; D Caballero
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

Review 5.  B cells in chronic graft-versus-host disease.

Authors:  Stefanie Sarantopoulos; Bruce R Blazar; Corey Cutler; Jerome Ritz
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-12       Impact factor: 5.742

6.  NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report.

Authors:  Howard M Shulman; Diana M Cardona; Joel K Greenson; Sangeeta Hingorani; Thomas Horn; Elisabeth Huber; Andreas Kreft; Thomas Longerich; Thomas Morton; David Myerson; Victor G Prieto; Avi Rosenberg; Nathaniel Treister; Kay Washington; Mirjana Ziemer; Steven Z Pavletic; Stephanie J Lee; Mary E D Flowers; Kirk R Schultz; Madan Jagasia; Paul J Martin; Georgia B Vogelsang; David E Kleiner
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-29       Impact factor: 5.742

Review 7.  Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions.

Authors:  Simona Pagliuca; David Michonneau; Flore Sicre de Fontbrune; Aurélien Sutra Del Galy; Aliénor Xhaard; Marie Robin; Régis Peffault de Latour; Gérard Socie
Journal:  Blood Adv       Date:  2019-08-13

8.  Risk stratification of organ-specific GVHD can be improved by single-nucleotide polymorphism-based risk models.

Authors:  D Kim; H-H Won; S Su; L Cheng; W Xu; N Hamad; J Uhm; V Gupta; J Kuruvilla; H A Messner; J H Lipton
Journal:  Bone Marrow Transplant       Date:  2014-03-03       Impact factor: 5.483

9.  Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis.

Authors:  Siribha Changsirikulchai; David Myerson; Katherine A Guthrie; George B McDonald; Charles E Alpers; Sangeeta R Hingorani
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-14       Impact factor: 8.237

10.  Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis.

Authors:  Jo Nadine Fleming; Howard M Shulman; Richard A Nash; Pamela Y Johnson; Thomas N Wight; Allen Gown; Stephen M Schwartz
Journal:  PLoS One       Date:  2009-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.